47
Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.
 INR was supratherapeutic: Effect; BCG: Treatment; phytonadione: Treatment; BCG: Treatment.Drug; phytonadione: Treatment.Drug; a week earlier: Treatment.Time_elapsed; after his fourth treatment: Treatment.Time_elapsed; BCG: Combination.Drug; phytonadione: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 INR was supratherapeutic: Effect; BCG: Treatment; phytonadione: Treatment; BCG: Treatment.Drug; phytonadione: Treatment.Drug; a week earlier: Treatment.Time_elapsed; after his fourth treatment: Treatment.Time_elapsed; BCG: Combination.Drug; phytonadione: Combination.Drug